Tuesday, 17 September 2019

Generics News

  • Glenmark's new generic gets FDA nod

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 21 Aug, 2015

    Singapore: Glenmark Pharmaceuticals(Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for Drospirenone and Ethinyl Estradiol Tablets USP...Read more

  • Amneal pharma to acquire Actavis Australia's generic business

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 02 Apr, 2015

    Singapore: US-based Amneal pharmaceuticals announced the acquisition of Actavis pharmaceuticals' generic business in Australia. The company has inked a binding letter of intent to acquire t...Read more

  • ANI pharma, IDT Australia to commercialize US generic drugs

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 18 Aug, 2015

    Singapore: ANI Pharmaceuticals, a global specialty pharmaceutical company recently announced collaboration with IDT Australia a global generic manufacturer, to commercialize up to 18 previo...Read more

  • Brickell Biotech-Kaken Pharma to co-develop dermatology drug

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 05 Apr, 2015

    Brickell Biotech Inc., a US-based clinical-stage pharmaceutical company has signed an exclusive license and development agreement for BBI-4000 with Kaken Pharmaceutical Co. Ltd., a top-tier...Read more

  • Lupin scouts for acquisitions across the world

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 09 Jul, 2013

    Singapore: Indian drug major Lupin Pharmaceuticals is set to expand its global footprint by scouting for acquisitions across the world. The company is looking at US, Japan, China and even t...Read more

  • US rheumatoid arthritis market to reach $9.3 bn by 2020'

    Generics |  Analysis | By BioSpectrum Bureau  | 0 Comment | 02 Apr, 2015

    Singapore: US treatment market for rheumatoid arthritis (RA) is set to increase in value from $6.4 billion in 2013 to $9.3 billion by 2020, representing a compound annual growth rate (CAGR)...Read more

  • BioSpectrum announces the hits and misses of 2013

    Generics |  Analysis | By BioSpectrum Bureau  | 0 Comment | 02 Jan, 2014

    Asia attracted a lot of interest from foreign multinational giants in the year 2013. This not only led to the increase in the number of acquisitions and mergers (M&A), it also led to a ...Read more

  • Teva proposes to buy Mylan for $40.1 billion

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 22 Apr, 2015

    Singapore: Israeli generic drug giant Teva pharmaceuticals made an unsolicited offer to buy US-based Mylan NV for about $40.1 billion, in the drug industry's largest takeover attempt this y...Read more

  • Teva's Potential $40 bn Mylan acquisition could transform generics space'

    Generics |  Analysis | By BioSpectrum Bureau  | 0 Comment | 27 Apr, 2015

    Singapore: Teva Pharmaceutical Industries' recent $40.1 billion offer to purchase Netherlands-based Mylan, which is crucially contingent on Mylan not consummating its offer to acquire Irish...Read more

  • TB claims 74000 children each year: WHO

    Generics |  Analysis | By BioSpectrum Bureau  | 0 Comment | 02 Oct, 2013

    Singapore: World Health Organization has launched "Roadmap for childhood TB: towards zero deaths", in an effort to prevent deaths of children from tuberculosis (TB) that claims nearly 74000...Read more

  • Boehringer, Lilly diabetes drug shows +ve results

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 25 Jun, 2013

    Singapore: Boehringer Ingelheim and Eli Lilly and Company have presented their results from two randomized phase III clinical trials evaluating the 'efficacy and safety of linagliptin in As...Read more

  • Indian drugmakers shifting R&D to South East Asia

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jul, 2013

    Singapore: Many leading Indian drug makers, that comprise a core part of the country's $1,000 bn worth pharmaceutical industry, are soon shifting their research and development operations a...Read more

  • Unlike FDA, Indian regulators finds no violations at Ranbaxy

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 20 Sep, 2013

    Singapore: India's Drugs Controller General of India (DCGI) has said that under the country's Drugs and Cosmetics Act, it has found 'no major violations' at Ranbaxy's Mohali plant that has ...Read more

  • Pfizer, Hisun launch generics joint venture in China

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 13 Sep, 2012

    Singapore: Pfizer and China's Zhejiang Hisun Pharmaceuticals, a leading Chinese pharmaceutical company, announced the launch of Hisun-Pfizer Pharmaceuticals, a joint venture formed between ...Read more

  • Teva launches generic of Abilify, antipsychotic drug

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 30 Apr, 2015

    Singapore: Teva Pharmaceutical has launched the generic equivalent to Abilify, aripiprazole tablets, an atypical antipsychotic medication, are approved for the treatment of schizophrenia an...Read more

  • Sun's generic of Takeda ulcer drug gets FDA nod

    Generics |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 16 Sep, 2013

    Singapore: Indian pharmaceutical major, Sun Pharmaceutical Industries announced that the generic version of Prevacid by the company has received that final approval from the US FDA. The Am...Read more

  • Teva to pay $718 mn to apex tax body in Israel

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 13 Nov, 2013

    Singapore: Israel-based Teva Pharmaceutical is going to pay $718 million to Israel Tax Authority to pay for the release of trapped profits, settling tax assessments for the years 2005-07 an...Read more

  • Sandoz gets FDA nod for MS generic drug

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 17 Apr, 2015

    Singapore: Sandoz, a Novartis company, has recieved USFDA approval of Glatopa, a first generic version of Teva's Copaxone (glatiramer acetate injection) for multiple sclerosis therapy. "Sa...Read more



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls